Sugi Predict

Sugi Predict / Compounds / SCHEMBL3175380

SCHEMBL3175380

SCHEMBL3175380

CC(C)(C)c1cc(N)n(-c2ccc(OCCN)cc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.43
▸ MAPK14 Q16539 7/20 0.41
▸ CDK8 P49336 5/20 0.41
▸ CSNK1A1 P48729 2/20 0.41
▸ CDK5 Q00535 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ RECQL P46063 1/20 0.39
▸ MAPK9 P45984 3/20 0.39
▸ MAPK13 O15264 2/20 0.39
▸ MAPK12 P53778 2/20 0.39
▸ MAPK11 Q15759 2/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16317130 0.89 LMNA (0.43) LMNAMAPK14CDK8CSNK1A1CDK5
SCHEMBL1410279 0.88 LMNA (0.46) LMNAMAPK14CDK8CSNK1A1CDK5
SCHEMBL20396179 0.86 MEN1 (0.50) LMNASMN1; SMN2RECQLMEN1NPC1
SCHEMBL28698599 0.86 CYP1A2 (0.47) LMNAMAPK14CDK8CSNK1A1CDK5
SCHEMBL4579387 0.86 ALDH1A1 (0.43) LMNAMAPK14CYP1A2CYP3A4MAPT
SCHEMBL10234078 0.84 SIGMAR1 (0.42) LMNAKMT2ACYP1A2MAPTCYP2C9
SCHEMBL15006973 0.82 MAPK13 (0.49) MAPK14MAPK9MAPK13MAPK12MAPK11
SCHEMBL28933422 0.82 KDM4E (0.54) MAPK14MAPK9MAPK13MAPK12MAPK11
SCHEMBL273437 0.81 LMNA (0.65) LMNAMAPK14SMN1; SMN2MAPK13MAPK12
SCHEMBL2082879 0.81 MAPK14 (0.47) MAPK14CDK8SMN1; SMN2RECQLMAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737283-B2 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2010-06-15 — — US disclosed
US-7666895-B2 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2010-02-23 — — US disclosed
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 — — US disclosed
US-20090137021-A1 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC 2009-05-28 — — US disclosed
US-7531566-B2 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2009-05-12 — — US disclosed
US-20090105230-A1 Anti-inflammatory medicaments FLYNN DANIEL L 2009-04-23 — — US disclosed
US-20090075986-A1 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC 2009-03-19 — — US disclosed
US-20090069310-A1 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC 2009-03-12 — — US disclosed
US-20080299639-A1 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC 2008-12-04 — — US disclosed
US-20080248548-A1 MODULATION OF PROTEIN FUNCTIONALITIES FLYNN DANIEL L 2008-10-09 — — US disclosed
US-7202257-B2 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC (US) 2007-04-10 — — US disclosed
US-20070037808-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-02-15 — — US disclosed
US-7144911-B2 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS LLC (US) 2006-12-05 — — US disclosed
US-20050288286-A1 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC 2005-12-29 — — US disclosed
EP-1585827-A2 MODULATION OF PROTEIN FUNCTIONALITIES Deciphera Pharmaceuticals, LLC (US) 2005-10-19 — — EP disclosed
EP-1585734-A2 ANTI-INFLAMMATORY MEDICAMENTS Deciphera Pharmaceuticals, LLC (US) 2005-10-19 — — EP disclosed
US-20040180906-A1 Anti-inflammatory medicaments DECIPHERA PHARMACEUTICALS, LLC 2004-09-16 — — US disclosed
US-20040171075-A1 Modulation of protein functionalities DECIPHERA PHARMACEUTICALS, LLC 2004-09-02 — — US disclosed
WO-2004060306-A2 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2004-07-22 — — WO disclosed
WO-2004061084-A2 MODULATION OF PROTEIN FUNCTIONALITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2004-07-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080248548-A1 MODULATION OF PROTEIN FUNCTIONALITIES C1QBP, SERPINA6, HSPBP1 LMNA 2365/4885MAPK14 2337/4885CDK8 2664/4885
US-20090105230-A1 Anti-inflammatory medicaments MIF, PTGES2, TNF LMNA 3791/4885MAPK14 56/4885CDK8 1843/4885
US-20090075986-A1 Anti-inflammatory medicaments MIF, PTGES2, TNF LMNA 3791/4885MAPK14 56/4885CDK8 1843/4885
US-20090069310-A1 Anti-inflammatory medicaments MIF, PTGES2, TNF LMNA 3791/4885MAPK14 56/4885CDK8 1843/4885
US-20070037808-A1 p38 kinase inhibitors MAPK1, MAP3K8, MAP3K1 LMNA 3620/4885MAPK14 29/4885CDK8 381/4885
US-20050288286-A1 Anti-inflammatory medicaments MIF, PTGES2, TNF LMNA 3791/4885MAPK14 56/4885CDK8 1843/4885
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS ABL2, ABL1, PTK2 LMNA 4513/4885MAPK14 80/4885CDK8 949/4885
US-20040180906-A1 Anti-inflammatory medicaments MIF, PTGES2, TNF LMNA 3791/4885MAPK14 56/4885CDK8 1843/4885
US-20090137021-A1 Anti-inflammatory medicaments MIF, PTGES2, TNF LMNA 3791/4885MAPK14 56/4885CDK8 1843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.